Understanding the long‐term impact of the COVID‐19 pandemic on non‐muscle‐invasive bladder cancer outcomes: 12‐Month follow‐up data from the international, prospective COVIDSurg Cancer study
Abstract Objective The objective of this study was to report the 12‐month oncological outcomes for patients with non‐muscle‐invasive bladder cancer (NMIBC) within the prospective, international COVIDSurg Cancer study. Patients and methods Eligible patients were aged ≥18 years and scheduled for elect...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-11-01
|
| Series: | BJUI Compass |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/bco2.432 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832591983457075200 |
|---|---|
| author | Cameron E. Alexander Arjun Nathan Alexander Light Chuanyu Gao Vinson Chan Sinan Khadhouri Kevin Gallagher Kevin G. Byrnes Michael Walters Terry Hughes Rita Perry Kelvin Okoth Laura Magill Thomas Pinkney Joseph B. John John S. McGrath Alexandra Colquhoun Yuhao Zhang James Blackmur Eric Etchill Stanley Tang Damián García Escudero Grant D. Stewart Veeru Kasivisvanathan COVIDSurg Collaborative |
| author_facet | Cameron E. Alexander Arjun Nathan Alexander Light Chuanyu Gao Vinson Chan Sinan Khadhouri Kevin Gallagher Kevin G. Byrnes Michael Walters Terry Hughes Rita Perry Kelvin Okoth Laura Magill Thomas Pinkney Joseph B. John John S. McGrath Alexandra Colquhoun Yuhao Zhang James Blackmur Eric Etchill Stanley Tang Damián García Escudero Grant D. Stewart Veeru Kasivisvanathan COVIDSurg Collaborative |
| author_sort | Cameron E. Alexander |
| collection | DOAJ |
| description | Abstract Objective The objective of this study was to report the 12‐month oncological outcomes for patients with non‐muscle‐invasive bladder cancer (NMIBC) within the prospective, international COVIDSurg Cancer study. Patients and methods Eligible patients were aged ≥18 years and scheduled for elective surgical management of NMIBC with curative intent (transurethral resection of bladder tumour [TURBT] or bladder biopsy) from 21 January to 14 April 2020. The primary outcome was disease recurrence within 12 months of previous elective TURBT/bladder biopsy. Secondary outcomes included disease progression within 12 months of previous elective TURBT/bladder biopsy, site‐declared delay to surgery from diagnosis as a consequence of COVID‐19 and deviation in standard care due to COVID‐19. Comparisons were made to cohorts from the pre‐pandemic era. Results Bladder cancer accounted for 2.2% (n = 446) of patients in the COVIDSurg Cancer study, with data contributed by 27 centres across 12 countries internationally. Within this included cohort, 229 patients had NMIBC and 12‐month follow‐up data available. On application of National Institute for Health and Care Excellence (NICE) criteria, 47.2% were classified as having high‐risk disease. Overall disease recurrence and progression rates were 29.3% and 9.7% at 12 months, respectively. In purely high‐risk pre‐pandemic cohorts, the International Bladder Cancer Group (IBCG) estimates a recurrence rate of 25% at 12 months, and the European Association of Urology (EAU) NMIBC 2021 scoring model estimates a 12‐month progression rate of 3.5%. As a consequence of the COVID‐19 pandemic, 10.9% of patients had site‐declared delay to TURBT/bladder biopsy; 7.4% did not undergo intravesical therapy or had early discontinuation of this; 9.2% did not undergo early repeat resection for high‐risk disease; and 18.3% had a delay to cystoscopic follow‐up surveillance. Conclusions This prospective study indicates that there were widespread deviations in usual care for NMIBC during the pandemic and that 12‐month oncological outcomes appear to be impaired compared to published pre‐pandemic outcomes. |
| format | Article |
| id | doaj-art-2b4d7c01b7db44c98fa0e5dde87a2b71 |
| institution | Kabale University |
| issn | 2688-4526 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Wiley |
| record_format | Article |
| series | BJUI Compass |
| spelling | doaj-art-2b4d7c01b7db44c98fa0e5dde87a2b712025-01-22T02:21:03ZengWileyBJUI Compass2688-45262024-11-015111158116510.1002/bco2.432Understanding the long‐term impact of the COVID‐19 pandemic on non‐muscle‐invasive bladder cancer outcomes: 12‐Month follow‐up data from the international, prospective COVIDSurg Cancer studyCameron E. Alexander0Arjun Nathan1Alexander Light2Chuanyu Gao3Vinson Chan4Sinan Khadhouri5Kevin Gallagher6Kevin G. Byrnes7Michael Walters8Terry Hughes9Rita Perry10Kelvin Okoth11Laura Magill12Thomas Pinkney13Joseph B. John14John S. McGrath15Alexandra Colquhoun16Yuhao Zhang17James Blackmur18Eric Etchill19Stanley Tang20Damián García Escudero21Grant D. Stewart22Veeru Kasivisvanathan23COVIDSurg CollaborativeLuton and Dunstable University Hospital Luton UKBritish Urology Researchers in Surgical Training (BURST) London UKBritish Urology Researchers in Surgical Training (BURST) London UKBritish Urology Researchers in Surgical Training (BURST) London UKBritish Urology Researchers in Surgical Training (BURST) London UKBritish Urology Researchers in Surgical Training (BURST) London UKBritish Urology Researchers in Surgical Training (BURST) London UKBritish Urology Researchers in Surgical Training (BURST) London UKBirmingham Centre for Observational and Prospective Studies University of Birmingham Birmingham UKBirmingham Centre for Observational and Prospective Studies University of Birmingham Birmingham UKBirmingham Centre for Observational and Prospective Studies University of Birmingham Birmingham UKBirmingham Centre for Observational and Prospective Studies University of Birmingham Birmingham UKBirmingham Centre for Observational and Prospective Studies University of Birmingham Birmingham UKBirmingham Centre for Observational and Prospective Studies University of Birmingham Birmingham UKUniversity of Exeter Medical School Exeter UKUniversity of Exeter Medical School Exeter UKCambridge University Hospitals NHS Foundation Trust Cambridge UKStepping Hill Hospital Stockport NHS Foundation Trust Stockport UKInstitute of Genetics and Cancer University of Edinburgh Edinburgh UKJohns Hopkins Hospital Baltimore Maryland USADivision of Surgery and Interventional Sciences University College London London UKHospital General Reina Sofía Murcia SpainCambridge University Hospitals NHS Foundation Trust Cambridge UKBritish Urology Researchers in Surgical Training (BURST) London UKAbstract Objective The objective of this study was to report the 12‐month oncological outcomes for patients with non‐muscle‐invasive bladder cancer (NMIBC) within the prospective, international COVIDSurg Cancer study. Patients and methods Eligible patients were aged ≥18 years and scheduled for elective surgical management of NMIBC with curative intent (transurethral resection of bladder tumour [TURBT] or bladder biopsy) from 21 January to 14 April 2020. The primary outcome was disease recurrence within 12 months of previous elective TURBT/bladder biopsy. Secondary outcomes included disease progression within 12 months of previous elective TURBT/bladder biopsy, site‐declared delay to surgery from diagnosis as a consequence of COVID‐19 and deviation in standard care due to COVID‐19. Comparisons were made to cohorts from the pre‐pandemic era. Results Bladder cancer accounted for 2.2% (n = 446) of patients in the COVIDSurg Cancer study, with data contributed by 27 centres across 12 countries internationally. Within this included cohort, 229 patients had NMIBC and 12‐month follow‐up data available. On application of National Institute for Health and Care Excellence (NICE) criteria, 47.2% were classified as having high‐risk disease. Overall disease recurrence and progression rates were 29.3% and 9.7% at 12 months, respectively. In purely high‐risk pre‐pandemic cohorts, the International Bladder Cancer Group (IBCG) estimates a recurrence rate of 25% at 12 months, and the European Association of Urology (EAU) NMIBC 2021 scoring model estimates a 12‐month progression rate of 3.5%. As a consequence of the COVID‐19 pandemic, 10.9% of patients had site‐declared delay to TURBT/bladder biopsy; 7.4% did not undergo intravesical therapy or had early discontinuation of this; 9.2% did not undergo early repeat resection for high‐risk disease; and 18.3% had a delay to cystoscopic follow‐up surveillance. Conclusions This prospective study indicates that there were widespread deviations in usual care for NMIBC during the pandemic and that 12‐month oncological outcomes appear to be impaired compared to published pre‐pandemic outcomes.https://doi.org/10.1002/bco2.432bladder cancerCOVID‐19delaynon‐muscle invasivepandemicsurgery |
| spellingShingle | Cameron E. Alexander Arjun Nathan Alexander Light Chuanyu Gao Vinson Chan Sinan Khadhouri Kevin Gallagher Kevin G. Byrnes Michael Walters Terry Hughes Rita Perry Kelvin Okoth Laura Magill Thomas Pinkney Joseph B. John John S. McGrath Alexandra Colquhoun Yuhao Zhang James Blackmur Eric Etchill Stanley Tang Damián García Escudero Grant D. Stewart Veeru Kasivisvanathan COVIDSurg Collaborative Understanding the long‐term impact of the COVID‐19 pandemic on non‐muscle‐invasive bladder cancer outcomes: 12‐Month follow‐up data from the international, prospective COVIDSurg Cancer study BJUI Compass bladder cancer COVID‐19 delay non‐muscle invasive pandemic surgery |
| title | Understanding the long‐term impact of the COVID‐19 pandemic on non‐muscle‐invasive bladder cancer outcomes: 12‐Month follow‐up data from the international, prospective COVIDSurg Cancer study |
| title_full | Understanding the long‐term impact of the COVID‐19 pandemic on non‐muscle‐invasive bladder cancer outcomes: 12‐Month follow‐up data from the international, prospective COVIDSurg Cancer study |
| title_fullStr | Understanding the long‐term impact of the COVID‐19 pandemic on non‐muscle‐invasive bladder cancer outcomes: 12‐Month follow‐up data from the international, prospective COVIDSurg Cancer study |
| title_full_unstemmed | Understanding the long‐term impact of the COVID‐19 pandemic on non‐muscle‐invasive bladder cancer outcomes: 12‐Month follow‐up data from the international, prospective COVIDSurg Cancer study |
| title_short | Understanding the long‐term impact of the COVID‐19 pandemic on non‐muscle‐invasive bladder cancer outcomes: 12‐Month follow‐up data from the international, prospective COVIDSurg Cancer study |
| title_sort | understanding the long term impact of the covid 19 pandemic on non muscle invasive bladder cancer outcomes 12 month follow up data from the international prospective covidsurg cancer study |
| topic | bladder cancer COVID‐19 delay non‐muscle invasive pandemic surgery |
| url | https://doi.org/10.1002/bco2.432 |
| work_keys_str_mv | AT cameronealexander understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT arjunnathan understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT alexanderlight understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT chuanyugao understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT vinsonchan understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT sinankhadhouri understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT kevingallagher understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT kevingbyrnes understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT michaelwalters understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT terryhughes understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT ritaperry understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT kelvinokoth understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT lauramagill understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT thomaspinkney understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT josephbjohn understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT johnsmcgrath understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT alexandracolquhoun understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT yuhaozhang understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT jamesblackmur understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT ericetchill understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT stanleytang understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT damiangarciaescudero understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT grantdstewart understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT veerukasivisvanathan understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy AT covidsurgcollaborative understandingthelongtermimpactofthecovid19pandemiconnonmuscleinvasivebladdercanceroutcomes12monthfollowupdatafromtheinternationalprospectivecovidsurgcancerstudy |